Myocardial ViabilityA.E. Iskandrian, E. van der Wall Springer Science & Business Media, 31 ene 2000 - 240 páginas AMI E. ISKANDRIAN & ERNST E. VAN DER WALL The first edition of this book was published in 1994. Since then important advances have occurred in the field of myocardial viability. This, coupled with increasing interest by the scientific community in the broader issues of its relevance to patient care, suggested to us the need to write the second edition. We are most fortunate to have the help of a distinguished group of experts who have helped shape the field; we appreciate their commitments and contributions. Almost all chapters have been radically modified. Chapter 1 deals with pathophysiology of myocardial hibernation and stunning; Chapter 2 with apoptosis; Chapter 3 with the role of positron emission tomography; Chapters 4 and 5 with the role of single photon emission computed tomography with thallium-201 and technetium agents, respectively; Chapter 6 with the role of SPECT fatty acid imaging; Chapter 7 with the role of SPECT FDG imaging; Chapter 8 with the role of cardiac catheterization angiography; Chapter 9 with the role of echocardiography; Chapter 10 with the role of magnetic resonance imaging; and Chapter 11 with clinical applications. Finally, Chapter 12 provides a short summary. |
Índice
Pathophysiological considerations | 1 |
2 Role of apoptosis in myocardial hibernation and myocardial stunning | 21 |
3 Assessment of myocardial viability with positron emission tomography | 47 |
4 Assessment of myocardial viability by thallium201 | 73 |
5 Technetium99mlabeled perfusion tracers for the detection of myocardial viability | 91 |
6 Fattyacid SPECT imaging for assessment of myocardial viability | 113 |
7 Role of FDG SPECT in viability assessment | 131 |
8 Detection of myocardial viability by angiographic methods | 147 |
9 Echocardiographic assessment of reversible left ventricular dysfunction | 155 |
10 Role of magnetic resonance techniques in viability assessment | 177 |
clinical applications | 199 |
12 Summary by the editors | 227 |
Index | 231 |
Otras ediciones - Ver todo
Myocardial Viability A.E. Iskandrian,Ernst E. van der Wall No hay ninguna vista previa disponible - 2012 |
Términos y frases comunes
acute myocardial infarction angina angiography apoptosis assessment of myocardial Bax JJ BMIPP caspase chronic coronary artery Circulation clinical Coll Cardiol compared comparison computed tomography contractile reserve coronary artery disease coronary revascularization demonstrated dipyridamole dobutamine stress echocardiography dose dobutamine echocardiography dysfunctional myocardium ejection fraction evaluated fatty acid FDG PET FDG SPECT FDG uptake fluorodeoxyglucose function after revascularization functional recovery glucose heart failure hibernating myocardium inotropic IPPA ISBN ischemic cardiomyopathy Iskandrian left ventricular dysfunction left ventricular ejection left ventricular function low dose dobutamine LV function LVEF magnetic resonance imaging myocardial blood flow myocardial ischemia myocardial perfusion myocardial viability nitrate nonviable normal patients with chronic patients with coronary positron emission tomography post-revascularization predictive value protein protocol quantitative regional myocardial reperfusion rest rest-redistribution revascularization reversible scintigraphy sestamibi severe left ventricular studies stunned myocardium technetium-99m techniques thallium thallium-201 imaging thallium-201 reinjection tissue tracer ventricular ejection fraction viability assessment viable myocardium wall motion abnormalities
Pasajes populares
Página 225 - The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
Página 225 - Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335: 1001-1009.